Kioxia Announces English Version of World’s First AI-Designed Manga
3.6.2020 12:30:00 EEST | Business Wire | Press release
Kioxia Corporation today announced that an English version of “PHAEDO,” a new manga created and designed by AI and human collaboration, inspired by the artistic style of manga legend Osamu Tezuka, will be released on June 3 as part of TEZUKA 2020, the first phase of Kioxia’s #FutureMemories brand campaign. PHAEDO, which debuted in February in Japanese comic magazine “Morning,” will be made available for English-language audiences on Kioxia’s TEZUKA 2020 website. PHAEDO is the world’s first1 international manga created through human collaboration, high-speed and large-capacity memory and advanced AI technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200603005356/en/
"PHAEDO" (Graphic: Business Wire)
The process of developing PHAEDO involved using AI technology to generate the story and create the characters. As a first step, to learn the essence of Tezuka’s work and his characteristics as a writer, AI analyzed 130 manga episodes, written and drawn by Osamu Tezuka, including globally famous titles such as “Astro Boy” and “Black Jack”. Based on this analysis, the AI then generated 129 candidate storylines. As a next step, the AI studied 6000 images and applied transfer learning to generate visuals for the characters.
By analyzing Tezuka’s works, AI was able to generate the physical characteristics of new characters, outlines of new stories, after which illustrators hand-drew clothing and other Tezuka inspired details and writers added dialogue. The project team consisted of engineers from Kioxia, who optimize semiconductor fab productivity and product performance using AI technology, illustrators and writers from Tezuka Productions Co., and AI researchers from Keio University and Future University Hakodate.
PHAEDO is the story of a homeless philosopher and his robot bird, Apollo, who try to solve crimes in Tokyo in 2030. This marks the first time Tezuka’s work has been recreated in 30 years.
Kioxia launched its #FutureMemories campaign last October to commemorate the company’s rebranding as Kioxia. PHAEDO is one of the many ways Kioxia intends to change the world by pursuing the potential of memory to create new value with never-before-seen experiences.
For details about PHAEDO, including videos and interviews, please visit TEZUKA 2020 website.
Notes
1. As of June 3, 2020. Kioxia Corporation research.
About Kioxia
Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. The company pioneers cutting-edge memory solutions and services that enrich people's lives and expand society's horizons. Kioxia's innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, SSDs, automotive and data centers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200603005356/en/
Contact information
For more information
Sam Ghirardello (phone: +81-3-5427-7396, SGhirardello@webershandwick.com)
Satoshi Ito (phone: +81-3-5427-7309, SIto@webershandwick.com)
Weber Shandwick (Tokyo)
Natalie Telson (ntelson@webershandwick.com)
Weber Shandwick (New York)
Public Relations
Kota Yamaji (kioxia-hd-pr@kioxia.com
)
Kioxia Holdings Corporation
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 16:00:00 EEST | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's core mission has always been to increase access to life-saving treatments. It’s about getting the right information to the right care tea
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 16:00:00 EEST | Press release
Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become operational infrastructure without corresponding security maturity. The report also reveals that AI environments are rapidly becoming more interconnected and business critical. Among organizations adopting AI, 64% now run vector databases, 55
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 16:00:00 EEST | Press release
As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructure to monitor airspace activity. The new 86,350-square-foot facility is a major step in readying supply for multiple, large, global markets. The
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 15:51:00 EEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis9.7.2026 15:45:00 EEST | Press release
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709701277/en/ “This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and develo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom